<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05013372</url>
  </required_header>
  <id_info>
    <org_study_id>CD147-CAR T for R/R T-NHL</org_study_id>
    <nct_id>NCT05013372</nct_id>
  </id_info>
  <brief_title>CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Pioneering Study on the Safety and Efficacy of CD147-Chimeric Antigen Receptor (CAR) T Cells in Patients With Relapsed or Refractory T-cell Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The safety and preliminary effectiveness of CD147-CAR T cells in patients with relapsed or&#xD;
      refractory T cell non-Hodgkin's lymphoma will be investigated in this pioneering study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CD147 has been demonstrated higher and relatively specific expression on T cell non-Hodgkin's&#xD;
      lymphoma. Preclinical studies have shown that CAR T cells targeting CD147 antigen can&#xD;
      continuously eliminate Jurkat T-cell lymphoma in mice and extend survival without severe&#xD;
      adverse events including hemolysis. Preliminary investigation of CD147-CAR T cells in solid&#xD;
      tumors has started and shown an acceptable safety profile. The safety and preliminary&#xD;
      effectiveness of CD147-CAR T cells in patients with relapsed or refractory T cell&#xD;
      non-Hodgkin's lymphoma will be investigated in this pioneering study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>within 12 months</time_frame>
    <description>The highest dose that does not cause unacceptable side effects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT)</measure>
    <time_frame>within 12 months</time_frame>
    <description>Side effects serious enough to prevent an increase in dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>within 12 months</time_frame>
    <description>Adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious adverse events (SAE)</measure>
    <time_frame>within 12 months</time_frame>
    <description>Serious adverse events (SAE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events of special interest (AESI)</measure>
    <time_frame>within 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>At the 12th week, 6th month, 9th month and 12th month</time_frame>
    <description>Overall response rate (ORR) evaluated according to the Lugano2014 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate (CR)</measure>
    <time_frame>At the 12th week, 6th month, 9th month and 12th month</time_frame>
    <description>Complete response rate (CR) evaluated according to the Lugano2014 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>At the 12th week, 6th month, 9th month and 12th month</time_frame>
    <description>Duration of response (DOR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of CD147-CAR T cells</measure>
    <time_frame>within 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of CD147-CAR T cells</measure>
    <time_frame>within 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of CD147-CAR T cells</measure>
    <time_frame>within 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>T-cell Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>Dose-escalation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Dose -1：0.1×10E+6/kg Dose 1：0.25×10E+6/kg Dose 2：0.5×10E+6/kg Dose 3：1.0×10E+6/kg Dose 4：2.0×10E+6/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD147- CAR T cells</intervention_name>
    <description>CAR T cells targeting CD147</description>
    <arm_group_label>Dose-escalation</arm_group_label>
    <other_name>CAR T cells targeting CD147</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject must meet all of the following criteria:&#xD;
&#xD;
               1. 18-65 years old;&#xD;
&#xD;
               2. Relapsed or refractory T-NHLs, including peripheral T-cell lymphoma, not&#xD;
                  otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL),&#xD;
                  ALK-positive ALCL, ALK-negative Image result for anaplastic large cell lymphoma&#xD;
                  (ALCL), enteropathy-related T-cell lymphoma, hepatosplenic T-cell lymphoma, etc.;&#xD;
&#xD;
               3. Previously received ≥2 lines of treatment without a complete response;&#xD;
&#xD;
               4. Immunohistochemical detection of tumor cells CD147 positive;&#xD;
&#xD;
               5. ECOG score 0-2;&#xD;
&#xD;
               6. The collection of mononuclear cells can be performed upon the judgment of the&#xD;
                  researcher;&#xD;
&#xD;
               7. No contraindications for allogeneic hematopoietic stem cell transplantation&#xD;
                  (AlloHCT);&#xD;
&#xD;
               8. Have donors for AlloHCT;&#xD;
&#xD;
               9. Agree for sequential treatment of AlloHCT;&#xD;
&#xD;
              10. Without serious organ dysfunction in 2 weeks before CAR-T infusion:&#xD;
&#xD;
                    1. Heart: without arrhythmia, LVEF≥50%, and without pericardial effusion;&#xD;
                       without heart failure (NYHA class III or IV) within12 months before CAR-T&#xD;
                       infusion; without myocardial infarction within 12 months before CAR-T&#xD;
                       infusion; without long-QT syndrome or secondary QT interval prolongation;&#xD;
&#xD;
                    2. Liver: ALT&lt;2 times the upper limit of normal (ULN) and TBIL&lt;1.5 times ULN,&#xD;
                       without active hepatitis;&#xD;
&#xD;
                    3. APTT and PT&lt;1.5 times ULN;&#xD;
&#xD;
                    4. Kidney: Serum creatinine &lt;1.5 mg/dl; or if the serum creatinine exceeds the&#xD;
                       upper limit, eGFR (CKD-EPI formula) needs to be &gt; 50 ml/min;&#xD;
&#xD;
                    5. Fingertip blood oxygen saturation ≥ 92%.&#xD;
&#xD;
              11. Estimated survival ≥ 3 months;&#xD;
&#xD;
              12. Sexually active patients must be willing to use an effective method of birth&#xD;
                  control during the study period and within 6 months after the study ending, and&#xD;
                  male partners should use condoms;&#xD;
&#xD;
              13. The patient is willing to join this clinical trial and sign an informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anyone who has one or more of the following:&#xD;
&#xD;
               1. A history of other malignancies with a disease-free period &lt; 5 years (except for&#xD;
                  cured basal cell carcinoma of the skin, cured cervical carcinoma in situ, and&#xD;
                  gastrointestinal tumors proven to be cured by endoscopic mucosal resection);&#xD;
&#xD;
               2. Those who have received allogeneic hematopoietic stem cell transplantation or&#xD;
                  organ transplantation;&#xD;
&#xD;
               3. Patients with bone marrow involvement;&#xD;
&#xD;
               4. Those who are allergic to the biological agents in CAR-T cell product ;&#xD;
&#xD;
               5. Pregnant or breastfeeding;&#xD;
&#xD;
               6. Active bacterial, fungal or viral infection;&#xD;
&#xD;
               7. Receiving systemic hormone therapy 1 week before participating in the clinical&#xD;
                  trial;&#xD;
&#xD;
               8. Have received other gene therapy before;&#xD;
&#xD;
               9. HBV or HCV infection or carrier is defined as: HBsAg positive or HBV-DNA&#xD;
                  positive; anti-HCV positive and HCV-RNA positive;&#xD;
&#xD;
              10. Active HIV infection;&#xD;
&#xD;
              11. Clinical diagnosis of virus infection or uncontrolled virus activation, including&#xD;
                  cytomegalovirus (CMV), adenovirus (ADV), BK virus or human herpesvirus 6 (HHV-6),&#xD;
                  etc.;&#xD;
&#xD;
              12. Central nervous system lymphoma (CNSL) is defined as the presence of ≥5 tumor&#xD;
                  cells/ ul in cerebrospinal fluid (CSF) or MRI suggested CNSL; any other CNS&#xD;
                  diseases, such as uncontrolled epilepsy, cerebral ischemia/hemorrhage, dementia,&#xD;
                  cerebellar disease or any autoimmune disease involving the central nervous&#xD;
                  system, or received treatment for central nervous system or brain metastasis&#xD;
                  (radiotherapy, surgery or other treatments);&#xD;
&#xD;
              13. Imaging determined lung infection;&#xD;
&#xD;
              14. Inappropriate to participate in the trial with investigators' decision.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaojun Huang, MD. PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shenmiao Yang, MD.</last_name>
    <phone>13439999810</phone>
    <email>yangshenmiao@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaojun Huang, MD. PhD.</last_name>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2021</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>Xiao-Jun Huang</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>CAR T cells</keyword>
  <keyword>T-cell Non-Hodgkin's lymphoma</keyword>
  <keyword>CD147</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

